Recs

5

Is SXC Health Solutions' Cash Flow Just for Show?

Although business headlines still tout earnings numbers, many investors have moved past net earnings as a measurement of a company's economic output. That's because earnings are very often less trustworthy than cash flow, since earnings are more open to manipulation based on dubious judgment calls.

Earnings' unreliability is one of the reasons Foolish investors often flip straight past the income statement to check the cash-flow statement. In general, by taking a close look at the cash moving in and out of the business, you can better understand whether the last batch of earnings brought money into the company or merely disguised a cash gusher with a pretty headline.

Calling all cash flows
When you're trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow (FCF) once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That brings us to SXC Health Solutions (Nasdaq: SXCI  ) , whose recent revenue and earnings are plotted below.

anImage

Source: Capital IQ, a division of Standard & Poor's. Data is current as of last fully reported fiscal quarter. Dollar values in millions. FCF = free cash flow. FY = fiscal year. TTM = trailing 12 months.

Over the past 12 months, SXC Health Solutions generated $90.4 million in FCF while it booked net income of $68.2 million. That means it turned 3.5% of its revenue into FCF. That sounds OK. But since a single-company snapshot doesn't offer much context, it always pays to compare that figure with those of sector and industry peers and competitors, to see how your company stacks up.

Company

TTM Revenue

TTM FCF

TTM FCF Margin

SXC Health Solutions $2,594 $90 3.5%
Express Scripts (Nasdaq: ESRX  ) $44,929 $1,495 3.3%
MedcoHealth Solutions (NYSE: MHS  ) $66,677 $1,886 2.8%
BioScrip (Nasdaq: BIOS  ) $1,743 $19 1.1%

Source: Capital IQ, a division of Standard & Poor's. Data is current as of last fully reported fiscal quarter. Dollar values in millions. FCF = free cash flow. TTM = trailing 12 months.

All cash is not equal
Unfortunately, the cash-flow statement isn't immune from nonsense, either. That's why it pays to take a close look at the components of cash flow from operations, to make sure that the cash flows are of high quality. What does that mean? To me, it means they need to be real and replicable in the upcoming quarters, rather than being offset by continual cash outflows that don't appear on the income statement, such as major capital expenditures.

For instance, cash flow based on cash net income and adjustments for non-cash income-statement expenses, like depreciation, is generally favorable. An increase in cash flow based on stiffing your suppliers (by increasing accounts payable for the short term) or shortchanging Uncle Sam on taxes will come back to bite investors later. The same goes for decreasing accounts receivable; it's good to see, but it's ordinary in recessionary times, and you can increase collections only so much. Finally, adding stock-based compensation expenses back to cash flows is questionable when a company hands out a lot of equity to employees and uses cash in later periods to buy back those shares.

So how does the cash flow at SXC Health Solutions look? Take a peek at the following chart, which flags questionable cash-flow sources with a red bar.

anImage

Source: Capital IQ, a division of Standard & Poor's. Data is current as of last fully reported fiscal quarter. Dollar values in millions. TTM = trailing 12 months.

When I say "questionable cash-flow sources," I mean items such as changes in taxes payable, tax benefits from stock options, and asset sales, among others. That's not to say that companies booking these as sources of cash flow are weak, or are engaging in any sort of wrongdoing, or that everything that comes up questionable in my graph is automatically bad news. But whenever a company is getting more than, say, 10% of its cash from operations from these dubious sources, investors ought to make sure to refer to the filings and dig in.

With questionable cash flows actually reducing operating cash flow slightly, SXC looks clean. Within the questionable cash-flow figure plotted in the TTM period above, changes in taxes payable provided the biggest boost, at 15.1% of cash flow from operations. Overall, the biggest drag on FCF came from changes in accounts receivable, which represented 78.4% of cash from operations. Investors may also want to keep an eye on accounts receivable, because the TTM change is 8.3 times greater than the average swing over the past five fiscal years.

A Foolish final thought
Most investors don't keep tabs on their companies' cash flow. I think that's a mistake. If you take the time to read past the headlines and crack a filing now and then, you're in a much better position to spot potential trouble early. Better yet, you'll improve your odds of finding the underappreciated home-run stocks that provide the market's best returns.

We can help you keep tabs on your companies with My Watchlist, our free, personalized stock-tracking service.

The Steve Jobs Betrayal
You may already know that in the final year of his life, Jobs revealed a stunning betrayal — and told his biographer, "I will spend my last dying breath... and every penny of Apple's $40 billion in the bank to right this wrong." What was it that made Jobs so irate — and why could it make a few in-the-know investors some major profits over the coming months and years?

Enter your email address below to find out what made Jobs so enraged!

The Motley Fool owns shares of MedcoHealth Solutions. Motley Fool newsletter services have recommended SXC Health Solutions and MedcoHealth Solutions. Try any of our Foolish newsletter services free for 30 days.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings. He is a co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On May 24, 2011, at 11:07 AM, EarlBerger wrote:

    I have owned SXC since it was a piece of a now-dissolved health and biotechnology fund, which also included TM Bioscience, now owned by Luminex (also a company with an interesting set of products). I recall meeting the president of System Xcellence about 10 years ago at a lunch and he remarked, apropos of the disappointing performance of the company after the fund dissolved, that they had made some changes and that I 'would like what I saw'. Since then the company expanded into the US and the stock is up more than 200% from the last time I bought it; and it appears to be a high focused and highly disciplined company worth the long haul

Add your comment.

Compare Brokers

Fool Disclosure

DocumentId: 1497909, ~/Articles/ArticleHandler.aspx, 5/27/2012 11:19:41 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 12,454.83 -74.92 -0.60%
S&P 500 1,317.82 -2.86 -0.22%
NASD 2,837.53 -1.85 -0.07%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

4/2/2012 8:00 PM
MHS $70.30 Down +0.00 +0.00%
Medco Health Solut… CAPS Rating: *****
SXCI $91.34 Up +1.51 +1.68%
SXC Health Solutio… CAPS Rating: ****
BIOS $6.73 Down -0.02 -0.30%
BioScrip, Inc. CAPS Rating: **
ESRX $52.63 Up +0.96 +1.86%
Express Scripts, I… CAPS Rating: ****

Advertisement